When was PolyAurum founded?

PolyAurum was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is PolyAurum located?

PolyAurum is headquartered in Philadelphia, United States.

How many employees does PolyAurum have?

As of Jul 01, 2024, the latest employee count at PolyAurum is 3.

Is PolyAurum a funded company?

PolyAurum is a funded company, having raised a total of $***** in its 1st and only funding round, a Grant (prize money) round on Sep 30, 2017.

When was the latest funding round of PolyAurum?

PolyAurum's latest funding was a $***** Grant (prize money) round on Sep 30, 2017, with participation from 1 investor.

Where does PolyAurum rank among its competitors?

PolyAurum ranks 171st amongst 348 active competitors, of which 108 are funded. The most recent competitor to raise funding was Helex, which secured $3.5M in Oct, 2025.

Who are the top competitors of PolyAurum?

PolyAurum's top competitors include Sirnaomics, Acorda and Aera. Among them, Helex secured the most recent funding round in October, 2025.

PolyAurum - 2026 Company Profile, Funding & Competitors

PolyAurum is a funded company based in Philadelphia (United States), founded in 2015. It operates as a Developer of biodegradable gold nanoparticles (BGNP) for diagnostic and therapeutic indications. PolyAurum has raised an undisclosed amount in funding. The company has 348 active competitors, including 108 funded and 31 that have exited. Its top competitors include companies like Sirnaomics, Acorda and Aera.

Company Details

Developer of biodegradable gold nanoparticles (BGNP) for diagnostic and therapeutic indications. The products enhance the absorption of radiation and are excretable as it encapsulates small gold nanoparticles in a biodegradable polymer. Finds application as a contrast agent for diagnostic imaging techniques such as computed tomography or photoacoustics.

Website: polyaurum.com
Email ID: *****@polyaurum.com

Key Metrics

Founded Year

2015

Location

Philadelphia, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Sep 30, 2017, $*****

Investors

JLABS & 1 more

Ranked

171^st among 348 active competitors

Employee Count

3 as on Jul 01, 2024

Similar Companies

Sirnaomics & 434 more

View PolyAurum's full profile

PolyAurum has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Sep 30, 2017 for $*****. 1 investor participated in its latest round. PolyAurum has 2 institutional investors.

Here is the list of recent funding rounds of PolyAurum:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 30, 2017	8720580	Grant (prize money)	7426080	9162605	6836200	8376111

Access funding benchmarks and valuations. Sign up today!

View details of PolyAurum's funding rounds and investors

PolyAurum's employee count trend

PolyAurum has 3 employees as of Jul 24. Here is PolyAurum's employee count trend over the years:

Uncover PolyAurum's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PolyAurum include Sirnaomics, Acorda and Aera. Here is the list of Top 10 competitors of PolyAurum, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Yuexiu Group & 16 others	67/100
2nd	Acorda 1995, Ardsley (United States), Acquired	Developer of therapies that restore neurological function	$66.5M	Saints Capital, Forbion & 15 others	65/100
3rd	Aera 2021, Boston (United States), Series B	Developer of genetic medicines across a wide range of therapeutic areas	$193M	Lux Capital, Arch Venture Partners & 2 others	60/100
4th	Vaxxas 2010, Brisbane (Australia), Series D	Developer of vaccines to treat cancer and infectious diseases	$91.2M	One Ventures, UniQuest & 12 others	59/100
5th	Clene Nanomedicine 2012, Salt Lake City (United States), Public	Developer of therapeutics for the treatment of neurodegenerative diseases	$42.5M	KSV Global, Pulsar Capital Management & 7 others	58/100
6th	Topas Therapeutics 2016, Hamburg (Germany), Series B	Developer of nanoparticle-based therapeutics for immunology disorders	$68.5M	Boehringer Ingelheim Venture Fund, Epidarex Capital ... & 7 others	57/100
7th	Helex 2021, New York City (United States), Seed	Provider of next-generation gene-editing therapies	$6M	pi Ventures, IndieBio & 2 others	57/100
8th	Arcturus Therapeutics 2013, San Diego (United States), Public	Developer of RNAi technologies for the treatment of rare orphan diseases	$1.3M	Cystic Fibrosis Foundation, JLABS & 1 others	57/100
9th	Splice Bio 2020, Barcelona (Spain), Series B	Provider of a proprietary platform for gene therapy	$192M	Ysios Capital, EQT & 8 others	57/100
10th	Alltrna 2018, Cambridge (United States), Series B	Developer of tRNA medicines for various therapeutic areas	$109M	Flagship Pioneering	56/100
171st	PolyAurum 2015, Philadelphia (United States), Funding Raised	Developer of biodegradable gold nanoparticles (BGNP) for diagnostic and therapeutic indications	-	JLABS, HHS	27/100